Table 3.
Comparison of antimicrobial susceptibility pattern of Gram negative bacteria in blood samples between pre-COVID and COVID period.
| Blood | Escherichia Coli | Klebsiella pneumoniae | Pseudomonas aeruginosa | Acinetobacter baumannii | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre-COVID-19 Period (27) | COVID-19 Period (23) | p-Value | Pre-COVID-19 Period (81) | COVID-19 Period (31) | p-Value | Pre-COVID-19 Period (6) | COVID-19 Period (10) | p-Value | Pre-COVID-19 Period (53) | COVID-19 Period (13) | p-Value | |
| Gentamicin | 70 | 66.6 | 0.7609 | 32.3 | 25 | 0.3474 | 65 | 75 | 0.1646 | 29 | 20 | 0.1881 |
| Amikacin | 76 | 100 | 0.0001 | 31 | 16.6 | 0.0307 | 66 | 100 | 0.0001 | 23 | 20 | 0.7310 |
| Cefotaxime | 36 | 11.1 | 0.0001 | 3.5 | 8.3 | 0.3727 | NR | NR | - | 10 | 20 | 0.0734 |
| Ciprofloxacin | 36 | 33.3 | 0.3801 | 36 | 16.6 | 0.0037 | 60 | 50 | 0.2007 | 26 | 20 | 0.4010 |
| Imipenem | 80 | 88.8 | 0.1170 | 52 | 25 | 0.0001 | 83 | 75 | 0.2240 | 7 | 20 | 0.0119 |
| Cotrimoxazole | 36 | 22.2 | 0.0423 | 25 | 16.6 | 0.2240 | NR | NR | - | 31 | 20 | 0.1042 |
| Piperacillin + Tazobactam | 59 | 55.5 | 0.6684 | 11 | 16.6 | 0.3083 | 100 | 100 | 1.00 | 33 | 20 | 0.0539 |
| Ceftazidime | NR | NR | - | NR | NR | - | 66 | 25 | 0.0001 | NR | NR | - |
NR—Not recommended according to CLSI; p < 0.05 was considered significant.